November 7, 2017 5:59pm
Another I told you so … “It was expected as the overbought became the targets of profit-taking while the sector prepared for this week’s loss-per-share quarterlies of those on the “usual suspect” list”
Bottom line there was nothing new and potentially rewarding discussed (in quarterly calls) today in “our’ universe – response, YAWN!
Pre-open indications: 5 hit and 0 miss
Regenerative Medicine Earnings Scorecard - Q3/2017 - to date … https://www.regmedinvestors.com/articles/9981
How right does one have to be? You could and should be reading this review of the day’s share pricing activity?
Is the truth so hard to fathom – that’s why my readership has grown exponentially!
Tuesday’s results have implications to Wednesday’s sector activity as a daily report may say little or a lot and it serves as insurance that all indications are being examined and evaluated!
Henry’omics:
From the pre-open’s newsletter, “companies’ loyalty to investors has just slipped away. Increased selling by the sector’s retail core has evolved into holdings by ETFs and dark (trading) pools. Somewhere in the evolving relationship with the market, the potential for destructive behavior was kept largely in check by the SEC but not now!
Managements now see that investors are their key versus ETF exposure and algorithm rules. It’s all about the care, salving and feeding of those who will stay with them!
- Just another down day for sector equities as multiple and quarterly conference calls set the tone – YAWN!
Traders are “dumping” and are selling no matter what as volatility heightens in our universe.
After listening to conference calls – the most BORING was Applied Genetic Technologies (AGTC) – as usual, the CEO didn’t address shareholder issues – classic AVOIDANCE while the CFO had the chance to illuminate some positives – stuck to a script – maybe he should get a mind or tongue of his own!!
- The theme of the day – KISS your shareholders GOODBYE … unless you can better show them the way forward!
Key words of the conference call ... INCONSISTENT results!
BOTTOM LINE of today's event ... there is nothing new and potentially rewarding articulated (in quarterly calls) today … in “our’ universe.
NO one (of those I followed today) sold me on their future …
The advance/decline line scenario of 43 SCGT & RT covered companies:
· The open was barely positive with an A/DL of 18/17 and 8 flats ;
· The mid-day was negative with an A/DL of 5/36 and 2 flats;
· The close was negative with an A/DL of 8/33 and 2 flats;
Pre-open indications: 5 hits and 0 miss
- Applied Genetic Technologies (AGTC) closed down -$0.05 – hit;
- Capricor (CAPR) closed down -$0.14 – hit;
- Cellectis SA (CLLS) closed up +$0.47 – hit;
- Juno Therapeutics (JUNO) closed down -$0.47 – hit;
- Vericel (VCEL) closed down -$0.075 – hit;
Some of MY working trend lines or indications:
… The greatest volume to the downside: RENE.L, VCEL, JUNO, IMUC and NWBO
… Upside volume was weighted to: MDXG, BSTG, BLUE, QURE and CLLS
… Biggest $ downside: ONCE (-$2.04), RGNX (-$1.40), STML (-$0.55), SGMO (-$0.50) and JUNO (-$0.47)
… Largest $ upside: BLUE (+$1.95), CLLS (+$0.47), QURE (+$0.39), MDXG (+$0.38) and AXGN (+$0.20)
… Flat: CYTX and ISCO
Daily analytics:
Small gains and losses on Tuesday as the broader market were weighed down by selloffs.
· The Dow ended with a gain of 8.81 points, or less than 0.1%, at 23,557.23.
· The S&P 500 index closed less than a point lower at 2,590.64, retreating from an intraday record set earlier in the session.
· The NASDAQ declined 18 points, or 0.3%, to 6,767.78.
The CBOE Volatility Index (VIX) widely considered the best gauge of fear in the market; Tuesday traded at 9.89, up +5.21% …
- Monday traded at 9.40, up +2.84% after Friday traded at 9.14, down -7.96% after Thursday traded 9.92, down -2.75% after Wednesday traded at 10.20, up +0.20% and last Tuesday traded 10.18 down -3.05% …
Welcome to another day of the sector’s roller coaster …
… The iShares Russell 2000 (IWM) indicated:
· Tuesday was down -1.18%
· Monday +0.14%
· Friday -0.12%
· Thursday +0.30%
· Wednesday -0.66%
· Last Tuesday +0.72%
… The iShares NASDAQ Biotechnology (IBB) indicated:
· Tuesday was down -0.50%
· Monday -0.40%
· Friday +1.54%
· Thursday -0.04%
· Wednesday -0.63%
· Last Tuesday -0.78%
The count - decliners versus gainers:
……. look at the differences in the spreads as decliners jump and %
· Tuesday’s decliners ranged from -0.60% <NWBO -$0.001> to -8.60% <FCSC -$0.16> in 33 equities;
· Monday’s decliners ranged from -0.28% <ONCE -$0.23> to -7.36% <BLUE -$11.50> in 30 equities;
· Friday’s decliners ranged from -0.64% <ONVO -$0.01> to -3.21% <MESO -$0.17> in 10 equities;
· Thursday’s decliners ranged from -0.21% <QURE -$0.03> to -12.71% <CLLS -$3.71> in 20 equities;
· Wednesday’s decliners ranged from -1.68% <FATE -$0.08> to -16.65% <CLLS -$5.83> in 27 equities;
· Last Tuesday’s decliners ranged from -0.25% <KOOL -$0.01> to -8.11% <AGTC -$0.30> in 23 equities;
Versus
… Look at the percentage’s (%) and spreads …
· Tuesday’s gainers ranged from +0.20% <MESO +$0.01> to +3.15% <MDXG +$0.38> in 8 equities;
· Monday’s gainers ranged from +0.06% <IMUC +$0.0002> to +20.51% <VTGN -$0.16> in 10 equities;
· Friday’s gainers ranged from +0.23% <CYTX +$0.0009> to +16.44% <OSIR +$0.84> in 29 equities;
· Thursday’s gainers ranged from +0.26% <KOOL +$0.01 > to +24.01% <JUNO +$11.60> in 21 equities;
· Wednesday’s gainers ranged from +0.24% <AXGN +$0.05> to +11.43% <RENE.L +$0.20> in 14 equities;
· Last Tuesday’s gainers ranged from +0.05% <IMUC +$0.0002> to +29.38% <STML +$3.10> in 17 equities;
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
